Cellectis to Hold Third Quarter Earnings Call on Friday, November 5, 2021 at 8AM EDT
29 October 2021 - 7:37AM
Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the
“Company”), a gene-editing platform company with clinical-stage
immuno-oncology programs using allogeneic chimeric antigen receptor
(CAR)-T cells and gene therapy programs for genetic diseases,
announced that it will report its financial results for the third
quarter and first nine-month period ending September 30, 2021, on
Thursday, November 4, 2021, after the close of the US market. The
announcement will be followed by a conference call at 8:00 AM EDT /
2:00 PM CET on Friday, November 5, 2021, prior to the open of the
US market.
The live dial-in information for the conference call
is:
US & Canada only: +1 (877) 407-3104
International: +1 (201) 493-6792
In addition, a replay of the call will be
available until November 19th, by calling +1 877-660-6853 (Toll
Free US & Canada); +1 201-612-7415 (Toll Free
International).
Conference ID: 13724432
About Cellectis Cellectis
is a gene editing company, developing first of its kind therapeutic
products. Cellectis utilizes an allogeneic approach for CAR-T
immunotherapies in oncology, pioneering the concept of
off-the-shelf and ready-to-use gene-edited CAR T-cells to treat
cancer patients, and a platform to achieve therapeutic gene editing
in hemopoietic stem cells for various genetic disorders. As a
clinical-stage biopharmaceutical company with over 21 years of
expertise in gene editing, Cellectis is developing life-changing
cell therapy product candidates utilizing TALEN®, its gene editing
technology, and PulseAgile, its pioneering electroporation
system in order to treat diseases with unmet medical
needs. As part of its commitment to a cure, Cellectis
remains dedicated to its goal of providing lifesaving UCART product
candidates for multiple cancers including acute myeloid leukemia
(AML), B-cell acute lymphoblastic leukemia (B-ALL) and multiple
myeloma (MM). .HEAL is a new platform focusing on
hemopoietic stem cells to treat blood disorders, immunodeficiencies
and lysosomal storage diseases. Cellectis
headquarters are in Paris, France, with locations in New York City,
New York and Raleigh, North Carolina. Cellectis is listed on the
Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker:
ALCLS).
For more information,
visit www.cellectis.com Follow
Cellectis on social media: @cellectis, LinkedIn and
YouTube.
For further information, please
contact:
Media contacts: Margaret Gandolfo, Senior
Manager, Communications, +1 (646) 628 0300 Pascalyne
Wilson, Director, Communications, +33776991433,
media@cellectis.com
Investor Relation
contact: Eric Dutang, Chief Financial
Officer, +1 (646) 630
1748, investor@cellectis.com
Forward-looking Statements
This presentation contains “forward-looking”
statements within the meaning of applicable securities laws,
including the Private Securities Litigation Reform Act of 1995.
Forward-looking statements may be identified by words such as “at
this time,” “anticipate,” “believe,” “expect,” “on track,” “plan,”
“scheduled,” and “will,” or the negative of these and similar
expressions. These forward-looking statements, which are based on
our management’s current expectations and assumptions and on
information currently available to management, include statements
about our research and development projects and priorities, our
pre-clinical project development efforts and the timing of our
presentation of data. These forward-looking statements are made in
light of information currently available to us and are subject to
numerous risks and uncertainties, including with respect to the
numerous risks associated with biopharmaceutical product candidate
development as well as the duration and severity of the COVID-19
pandemic and governmental and regulatory measures implemented in
response to the evolving situation. With respect to our cash
runway, our operating plans, including product development plans,
may change as a result of various factors, including factors
currently unknown to us. Furthermore, many other important factors,
including those described in our Annual Report on Form 20-F and the
financial report (including the management report) for the year
ended December 31, 2020 and subsequent filings Cellectis makes with
the Securities Exchange Commission from time to time, as well as
other known and unknown risks and uncertainties may adversely
affect such forward-looking statements and cause our actual
results, performance or achievements to be materially different
from those expressed or implied by the forward-looking statements.
Except as required by law, we assume no obligation to update these
forward-looking statements publicly, or to update the reasons why
actual results could differ materially from those anticipated in
the forward-looking statements, even if new information becomes
available in the future.
- 20211028_Q3 Earnings Call PR_ENGLISH
Cellectis (NASDAQ:CLLS)
Historical Stock Chart
From Sep 2024 to Oct 2024
Cellectis (NASDAQ:CLLS)
Historical Stock Chart
From Oct 2023 to Oct 2024